Ashford Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.4M | Sell |
207,565
-6,213
| -3% | -$1.23M | 5.12% | 2 |
|
|
2025
Q4 | $40.4M | Sell |
213,778
-30,652
| -13% | -$5.89M | 4.5% | 2 |
|
|
2025
Q3 | $43.3M | Sell |
244,430
-58,097
| -19% | -$8.64M | 4.82% | 2 |
|
|
2025
Q2 | $34.4M | Buy |
302,527
+4,492
| +2% | +$480K | 4.04% | 2 |
|
|
2025
Q1 | $31.3M | Sell |
298,035
-12,629
| -4% | -$1.43M | 4.04% | 2 |
|
|
2024
Q4 | $33.3M | Buy |
310,664
+257
| +0.1% | +$29.1K | 3.93% | 2 |
|
|
2024
Q3 | $31.1M | Sell |
310,407
-11,800
| -4% | -$1.19M | 3.88% | 3 |
|
|
2024
Q2 | $27.1M | Buy |
322,207
+125,672
| +64% | +$10M | 3.67% | 5 |
|
|
2024
Q1 | $14.4M | Buy |
+196,535
| New | +$14.5M | 1.94% | 21 |
|
|
2022
Q1 | – | Sell |
-4,873
| Closed | -$470K | – | 108 |
|
|
2021
Q4 | $470K | Hold |
4,873
| – | – | 0.05% | 88 |
|
|
2021
Q3 | $424K | Hold |
4,873
| – | – | 0.04% | 95 |
|
|
2021
Q2 | $399K | Sell |
4,873
-321
| -6% | -$26.7K | 0.04% | 95 |
|
|
2021
Q1 | $494K | Sell |
5,194
-3,206
| -38% | -$303K | 0.05% | 88 |
|
|
2020
Q4 | $521K | Hold |
8,400
| – | – | 0.05% | 89 |
|
|
2020
Q3 | $499K | Sell |
8,400
-641
| -7% | -$43.7K | 0.06% | 80 |
|
|
2020
Q2 | $631K | Sell |
9,041
-2,340
| -21% | -$148K | 0.08% | 72 |
|
|
2020
Q1 | $516K | Buy |
+11,381
| New | +$645K | 0.09% | 70 |
|
|
2019
Q1 | – | Sell |
-140,471
| Closed | -$11.9M | – | 104 |
|
|
2018
Q4 | $11.9M | Buy |
140,471
+2,962
| +2% | +$316K | 1.95% | 22 |
|
|
2018
Q3 | $23.5M | Buy |
137,509
+329
| +0.2% | +$49.6K | 2.84% | 13 |
|
|
2018
Q2 | $17.7M | Sell |
137,180
-264
| -0.2% | -$29.5K | 2.34% | 15 |
|
|
2018
Q1 | $14.2M | Sell |
137,444
-67,719
| -33% | -$6.7M | 2.13% | 18 |
|
|
2017
Q4 | $17.5M | Sell |
205,163
-7,294
| -3% | -$632K | 2.73% | 11 |
|
|
2017
Q3 | $18M | Buy |
212,457
+449
| +0.2% | +$35.6K | 2.9% | 9 |
|
|
2017
Q2 | $16.1M | Buy |
212,008
+3,770
| +2% | +$264K | 2.8% | 10 |
|
|
2017
Q1 | $13.7M | Buy |
208,238
+15,222
| +8% | +$1M | 2.64% | 13 |
|
|
2016
Q4 | $12.2M | Buy |
193,016
+21,784
| +13% | +$1.37M | 2.46% | 13 |
|
|
2016
Q3 | $10.9M | Buy |
171,232
+4,902
| +3% | +$360K | 2.24% | 16 |
|
|
2016
Q2 | $12.4M | Buy |
166,330
+347
| +0.2% | +$25.8K | 2.77% | 11 |
|
|
2016
Q1 | $11.1M | Buy |
165,983
+201
| +0.1% | +$12.2K | 2.63% | 9 |
|
|
2015
Q4 | $11.2M | Buy |
165,782
+320
| +0.2% | +$19.8K | 2.64% | 13 |
|
|
2015
Q3 | $8.84M | Sell |
165,462
-4,512
| -3% | -$274K | 2.07% | 13 |
|
|
2015
Q2 | $10.7M | Sell |
169,974
-2,405
| -1% | -$131K | 2.36% | 9 |
|
|
2015
Q1 | $8.29M | Sell |
172,379
-1,122
| -0.6% | -$43K | 1.69% | 18 |
|
|
2014
Q4 | $5.76M | Sell |
173,501
-86
| -0% | -$2.8K | 1.15% | 34 |
|
|
2014
Q3 | $5.09M | Sell |
173,587
-53,191
| -23% | -$1.77M | 1.09% | 41 |
|
|
2014
Q2 | $8.81M | Sell |
226,778
-6,685
| -3% | -$271K | 1.77% | 16 |
|
|
2014
Q1 | $9.8M | Sell |
233,463
-111,539
| -32% | -$4.65M | 1.9% | 12 |
|
|
2013
Q4 | $11.3M | Sell |
345,002
-15,519
| -4% | -$506K | 2.16% | 13 |
|
|
2013
Q3 | $9.73M | Sell |
360,521
-130,092
| -27% | -$3.66M | 1.94% | 15 |
|
|
2013
Q2 | $11.4M | Buy |
+490,613
| New | +$8.82M | 2.48% | 4 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Ashford Capital Management's LGND Position: Q1 2026 in Review
Ashford Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 2.9% in Q1 2026, selling an estimated $1.23M and leaving 207,565 shares worth $41.4M. The position accounts for 5.12% of the portfolio, ranked #2.
Ashford Capital Management first reported a position in LGND in Q2 2013 and has held it in 40 quarters since. The position peaked at $43.3M in Q3 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Ashford Capital Management held 207,565 shares of Ligand Pharmaceuticals worth $41.4M as of Q1 2026.
- Ashford Capital Management sold 6,213 Ligand Pharmaceuticals shares in Q1 2026, an estimated $1.23M.
- Ligand Pharmaceuticals made up 5.12% of Ashford Capital Management's portfolio in Q1 2026, its #2 holding.
- Ashford Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
- Ashford Capital Management's Ligand Pharmaceuticals position peaked at $43.3M in Q3 2025.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Ashford Capital Management's 13F filing for Q1 2026, filed 15 May 2026.